Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00168701
Status:
COMPLETED
Last Update Posted:
2023-08-28
First Post:
2005-09-09
Brief Title:
Efficacy and Safety of BG00012 in MS
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
Double-Blind Placebo-Controlled Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Determine the efficacy safety and tolerability of BG00012 in MS patients
Detailed Description:
The study will be divided into two parts Part 1 will be a 24-week blinded placebo-controlled treatment phase followed by Part 2 a 24-week blinded safety extension phase in which all subjects will receive BG00012
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None